Enhanced Survival Rates with Initial Treatment
A study suggests that patients with cervical cancer who undergo an initial course of treatment prior to their standard treatment have a one-third reduced risk of mortality and disease recurrence.
Challenges in Current Therapeutic Approach
Chemoradiation, which involves concurrent radiotherapy and chemotherapy, has been the prevailing therapeutic approach since 1999. However, despite advancements in techniques, cancer recurs in as many as 30 percent of cases.
Promising Clinical Trial Results
A group from University College London enlisted 500 patients to participate in a ten-year clinical trial. All of them had cervical cancer that was visible in its unaltered size, even without a microscope.
“Start your investing journey with a gift! Claim your free Webull shares.”
While all participants underwent standard chemoradiation, a subset of them received an initial course of induction chemotherapy.
The intensive treatment, which maximizes the benefits of chemoradiation by destroying as many cancer cells as possible with drugs, has been associated with certain risks and may not be suitable for all patients.
However, preliminary analysis indicated that 80% of those who had undergone both treatments were still alive five years later, and 73% had not experienced a recurrence or metastasis of their malignancy.
In contrast, 72% of those in the standard treatment group were still alive, and 64% had not experienced a recurrence or metastasis of their illness.
Significant Prognostic Improvement
The study’s principal investigator, Dr. Mary McCormack, continued, “Our trial demonstrates that this brief course of additional chemotherapy administered immediately before standard CRT can reduce the risk of cancer recurrence or mortality by 35%. This is the most significant prognostic improvement for this disease in more than two decades.”
Cervical cancer predominantly affects women in their early 30s, with the United Kingdom receiving approximately 3,200 new diagnoses annually.
The research was financially supported by Cancer Research UK, which estimates that the five-year survival rate for cervical cancer is approximately 70%.
Implications for Cervical Cancer Treatment
Carboplatin and paclitaxel, which are necessary for induction chemotherapy, are accessible, affordable, and have already received patient approval, according to the researchers. Consequently, they could be rapidly integrated into standard treatment.
The executive director of research and innovation at Cancer Research UK, Dr. Iain Foulkes, described the outcomes as “remarkable.”
“Timing is crucial when it comes to treating cancer,” he advised. It reduces cancer recurrence and can be provided quickly using internationally available drugs.
Harvard scientists find link of colorectal cancer to breast milk.
